Lysosomal enhancement via vacuolar H+-ATPase remains experimental for protein misfolding neurodegenerative diseasesLysosome Boost May Help Misfolded Protein Diseases

This mini-review discusses the therapeutic potential of enhancing lysosomal activity for protein misfolding neurodegenerative diseases. The authors focus on compounds that physically associate with the lysosome to enhance or restore its activity, including the vacuolar H+-ATPase as a target. The central argument is that lysosomal activity may have broad applicability as a therapeutic modality across this disease category.

The review does not report a study population, sample size, comparator, or follow-up duration. No primary or secondary clinical outcomes are described, and no effect sizes, p-values, or confidence intervals are provided. The only result noted is qualitative: compounds that physically associate with the lysosome can enhance or restore its activity.

Safety data are not reported, including adverse events, serious adverse events, discontinuations, or tolerability. The authors acknowledge that the approach of directly targeting lysosomal activity remains experimental. Funding sources and conflicts of interest are also not reported.

Given the absence of clinical outcome data and the experimental status of this approach, the findings should be interpreted as hypothesis-generating. Clinicians should recognize that lysosomal enhancement via vacuolar H+-ATPase is not an established therapy for protein misfolding neurodegenerative diseases.